Fears stigma may judge hep C care

AUSTRALIA is poised to have the broadest access to hepatitis C medications in the world but researchers are concerned that stigma against drug and alcohol users may lead to discriminatory prescribing.

Cabinet is expected to consider recommendations for PBS listing of the drugs by early next year, which may lead to increased prescribing by GPs.

The Pharmaceutical Benefits Advisory Committee (PBAC) recommendations also include providing access to all people with chronic hepatitis C infection, regardless of drug or alcohol use.  

Hepatitis Australia’s policy